• 대한약침학회지
• /
• 제26권4호
• /
• pp.348-356
• /
• 2023

Objectives: Neuralgia-pharmacopuncture (NP) was recently developed as a water-soluble type of pharmacopuncture inspired by CS (care special pain)-pharmacopuncture. I aimed to evaluate the toxic response and approximate lethal dose of when NP when administered intramuscularly to Sprague Dawley rats. Methods: The experimental group was divided into the NP test substance group and the saline control group and administered at a dose of 1.0 mL/animal to the posterior thigh muscles on both sides using a 1 mL syringe; each group consisted of five males and five females. Each rat was monitored for clinical signs and changes in body weight for 14 days after a single intramuscular injection. After completing observation, necropsy findings and localized tolerance at the injection site were assessed via gross necropsy and histopathological examination. Results: No deaths occurred in the NP or control group, regardless of sex. During the observation period, no changes (such as general symptoms, weight change, or visual observation results at the time of autopsy) were judged to be due to the test substance. Histopathological examination showed no changes at the administration site judged to be caused by the test substance in either the male or female test substance administration groups. In addition, mononuclear cell infiltration of the outer membrane of the femoris muscle at the administration site was observed at the same frequency and extent in the control and NP groups, and was judged to be caused by physical stimulation by the injection needle; therefore, it had no toxicological significance. Conclusion: Based on the above results, the approximate lethal dose for a single intramuscular administration of the test substance NP in Sprague-Dawley rats was judged to be > 1.0 mL/animal, and there were no findings that were judged to be due to the test substance at the administration site.

• Korean Journal of Radiology
• /
• 제23권4호
• /
• pp.402-412
• /
• 2022

Objective: To evaluate the image quality and lesion detectability of lower-dose CT (LDCT) of the abdomen and pelvis obtained using a deep learning image reconstruction (DLIR) algorithm compared with those of standard-dose CT (SDCT) images. Materials and Methods: This retrospective study included 123 patients (mean age ± standard deviation, 63 ± 11 years; male:female, 70:53) who underwent contrast-enhanced abdominopelvic LDCT between May and August 2020 and had prior SDCT obtained using the same CT scanner within a year. LDCT images were reconstructed with hybrid iterative reconstruction (h-IR) and DLIR at medium and high strengths (DLIR-M and DLIR-H), while SDCT images were reconstructed with h-IR. For quantitative image quality analysis, image noise, signal-to-noise ratio, and contrast-to-noise ratio were measured in the liver, muscle, and aorta. Among the three different LDCT reconstruction algorithms, the one showing the smallest difference in quantitative parameters from those of SDCT images was selected for qualitative image quality analysis and lesion detectability evaluation. For qualitative analysis, overall image quality, image noise, image sharpness, image texture, and lesion conspicuity were graded using a 5-point scale by two radiologists. Observer performance in focal liver lesion detection was evaluated by comparing the jackknife free-response receiver operating characteristic figures-of-merit (FOM). Results: LDCT (35.1% dose reduction compared with SDCT) images obtained using DLIR-M showed similar quantitative measures to those of SDCT with h-IR images. All qualitative parameters of LDCT with DLIR-M images but image texture were similar to or significantly better than those of SDCT with h-IR images. The lesion detectability on LDCT with DLIR-M images was not significantly different from that of SDCT with h-IR images (reader-averaged FOM, 0.887 vs. 0.874, respectively; p = 0.581). Conclusion: Overall image quality and detectability of focal liver lesions is preserved in contrast-enhanced abdominopelvic LDCT obtained with DLIR-M relative to those in SDCT with h-IR.

• Radiation Oncology Journal
• /
• 제8권1호
• /
• pp.73-77
• /
• 1990

1981년부터 1989년까지 경희대학 부속병원 치료방사선과에서 무기폐를 동반한 폐암으로 방사선 치료를 받은 환자중, 과거력상 폐절제술, 항암요법, 방사선치료등의 기왕력이 있는 환자를 제외한 42명을 대상으로 치료성적을 분석하였다. 1. 비소세포성 폐암은 $62\%$ (21/34), 소세포성 폐암은 $75\%$ (6/8)에서 각각 무기폐가 방사선 치료 후 재팽창 되었으며, 전체 환자의 $64\%$ (27/42)에서 부분 또는 완전반응(reexpansion)을 나타내었다. 2. 방사선 총선량이 40 Gy (1297 ret) 이하와 40 Gy (1337 ret) 이상인 군에서 반응은 각각 $50\%$ (6/12)와 $70\%$ (21/30)이 었으며, 총선량과 무기폐 반응사이에는 유의한 관계가 있었다(p<0.01). 3. 분할조사선량에 따른 반응율은 소선량($180\~200$ cGy)에서는 $53\%$ (14/22), 대선량(300 cGy)에서는 $65\%$ (13/20)이었다. 4. 이상의 성적으로 보아 무기폐를 동반한 폐암 환자중에서, 특히 수술과 항암요법으로 치료가 곤란하고 조속한 처치를 요하는 비소세포성 폐암에서 방사선 치료의 중요한 역할이 확인되었다.

• International Journal of Industrial Entomology and Biomaterials
• /
• 제5권1호
• /
• pp.109-122
• /
• 2002

The purpose of this investigation is to evaluate the effects of the Nuegra on enhancement of the masculine and physical activities in general through measuring changes of the testosterone, FSH and subjective symptoms like fatigue, insomnia, urinary stream, muscular weakness, libido and erectile dysfunction. Total 168 male subjects were enrolled from 12 urology, internal medicine clinics and general practitioner, During the 6-week investigational period, 2 capsules of Nuegra were given to the subjects right after meal for 4 weeks, and 1 capsule of Nuegra was added each time in subjects with no or minimal effect. Testoster-one and FSH levels were measured at first visit and last visit, for evaluating masculine activities. To avoid bias and standardize the test results, only one clinic was assigned as a central lab, and all blood samples were transferred. General information and subjective symptoms were evaluated at first visit and at 2 weeks interval, week 2, 4 and 6 using VAS (Visual Analogue Scale). The mean age of the subjects were 51.8${\pm}$8.2 years old (range: 36.1-82.1). Based on the subjects who were tested on testosterone and FSH levels at day l and week 6, the means were 4.4${\pm}$1.4 nmol/L (range: 2.6-7.7), 8.6${\pm}$9.6 mIU/mL (range: 0.3-40.4), respectively at day 1. At week 6, the results were 4.9 ${\pm}$1.6 (2.6-8.9 range), 9.4${\pm}$13.1 (1.0-53.9 range), respectively. Marginally significant difference between pre-dose and post-dose was present. Statistically significant differences were revealed in general assessment for subjective symptoms, fatigue, insomnia, erectile dysfunction, etc. In fatigue, response rates were 39.6, 65.4 and 76.4% at week 2, 4 and 6, respectively (P < 0.0001). Response vates for erectile dysfunction were 13.4, 41.2 and 72.7% at week 2, 4, and 6 (P < 0.0001), respectively, Response rates for libido were 13.6, 51.6 and 73.5% at week 2, 4, and 6 (P < 0.0001), respectively. For urinary stream response rates were 26.9, 44.7 and 66.8% at week 2, 4, and 6 (P < 0.0001), respectively. VAS for muscular weakness did not show significant results that response rates were 40, 60 and 80% at week 2, 4, and 6 from 8.2 (P ＝ 0.24), respectively. Response rates for insomnia were 50, 60, 100% at week 2, 4, and 6 (P < 0.0001), respectively. The results shows that Nuegra tends to enhance masculine activities including libido, erectile dysfunction and urinary stream and also effective for improving general conditions especially insomnia, muscular weakness and fatigue. In conclusion, this investigation has demonstrated that Nuegra does not only have tendency to increase masculine activities through increased secretion of the testosterone and FSH but also improve general conditions such as erectile dysfunction, libido, fatigue and muscular power.

• Radiation Oncology Journal
• /
• 제13권3호
• /
• pp.233-241
• /
• 1995

Purpose : To analyse clinical outcome and prognostic factors according to treatment modality, this paper report our experience of retrospective study of patients with esophageal cancer Materials and Methods : One hundred and ten patients with primary esophageal cancer who were treated in Presbyterian Medical Center from May 1985 to December 1992. We analysed these patients retrospectively with median follow up time of 28 months, one hundred and four patients($95{\%}$) were followed up from 15 to 69 months. In methods, twenty-eight patients were treated with median radiation dose irradiated 54.3Gy only. Fifty-six patients were treated with combined chemoradiotherapy. Sixteen cases of these patients were treated with concurrent chemoradiation and the other patients(forty cases) were treated sequential chemoradiotherapy. In concurrent chemoradiotherapy group, patients received 5-FU continuous IV infusion for 4 days. Cisplatin IV bolus. and concurrent esophageal irradiation to 30 Gy. After that patients received 5-FU continuous IV, Cisplatin bolus injection and Mitomycin-C bolus IV, Bleomycin continuous IV, and irradiation to 20 Gy. In sequential chemoradiotherapy group, the chemotherapy consisted of 5-FU 1,000mg/$m^2$ administered as a continuous 24 hour intravenous infusion during five days and Cisplatin 80-100mg/$m^2$ bolus injected, or Bleomycin, Vinblastine, Cisplatin, Methotrexate were used of 1 or 2 cycles. After preoperative concurrentm chemoradiation twenty-six patients underwent radical esophagectomy. Results : Ninety-three patients could be examined for response assessment, By treatment modality, response rates were $85.1{\%}$ for radiation alone group and $86.3{\%}$ for combined chemoradiation group. But in operation group, after one cycle of concurrent chemoradiation treatment, response rate was $61.9{\%}$. The pathologic complete response were $15.4{\%}$ in operation group. Overall median survival was II months and actuarial 5-year survival rate was $8{\%}$. The median survival interval was 6 months for radiation alone group, 11 months for combined chemoradiation group and 19 months for operation group. And also median survival was 19 months for complete responder group that 8 months for noncomplete responder group. In univariative analysis, statistically significant prognostic factors were tumor size, clinical stage, tumor response, and operation. In multivariative analysis, significantly better survival was associated with clinical stage, tumor response, radiation dose, and operation. Conclusion : Compared with radiotherapy alone, combined multimodality may improve the median survival in patients with localized carcinoma of the esophagus and toxicity is acceptable.

• 대한본초학회지
• /
• 제29권3호
• /
• pp.59-70
• /
• 2014

Objectives : The purpose of this study was to evaluate boiled rice made from unpolished rice, Job's Tears, and extract from medicinal herbs mixture (HGMCJE) for hypoglycemic effect on STZ-induced diabetic rats. Methods : In the response of glucose tolerance, control and diabetic rats groups was intubated with glucose and HGMCJE. Furthermore, boiled 100% polished rice (P rice), boiled unpolished rice mixed with white rice and Job's tears (polished rice:unpolished rice:Job's tears=60:25:15, UPJ-rice), and UPJ rice made from HGMCJE (HUPJ-rice) were intubated to control and diabetic rats groups, respectively. Then, blood glucose concentration, incremental blood glucose, and area under the curve (${\Delta}AUC$) were analyzed in every experimental groups, and these data were used to evaluate glycemic response. Results : When glucose and p rice were intubated in control and diabetic rats, blood glucose concentration, incremental blood glucose, and incremental response ${\Delta}AUC$ of diabetic groups were significantly increase than control groups. But administraion of a single dose of extract from medicinal herbs mixture and HUPJ-rice in control and diabetic rats inhibited the remarkable increase the level of postprandial blood and ${\Delta}AUC$ at 60, 90, and 120 min Conclusions : These results indicate that when intubation of glucose and P rice were out of control on postprandial glycemic response in diabetic rats. But postprandial glycemic response was well-modulated by administrating a single oral dose of HGMCJE and HUPJ-rice. Therefore, HGMCJE can be developed as an effective hypoglycemic agent.

• 생물정신의학
• /
• 제3권2호
• /
• pp.240-244
• /
• 1996

흰쥐에 항정신병약물인 haloperidol을 장기간 투여한 뒤 줄무늬체와 후결절 조직에서의 DA $D_2$양 수용체의 변동에 대해 조사하였다. 약물투여군 4군에게 haloperidol을 각기 0.05, 0.15, 0.5, 1.5mg/kg/day이 되게끔 4주간 투여하였다. DA수용체의 변동은 [$^3H$]spiperone을 이용한 결합반응법을 통해 알아 보았다. 정상대조군에 비해 4주 동안 haloperidol을 투여받은 군 모두에서 줄무늬체에서의 DA 수용체의 최대 결합치가 증가한 것으로 나타났다. 기존의 연구에서 사용한 용량보다 대단히 낮은 0.05mg/kg/day을 투여받은 군 역시 유의한 증가를 보여 낮은 용량의 haloperidol이 DA계에 영향을 미치는 것을 알 수 있었다. 후결절조직의 최대결합치는 haloperidol투여군 모두에서 증가한 경향을 볼 수 있었으나 정상대조군에 비해 1.5mg/kg/day투여군에서 유의한 증가를 볼 수 있었다. 본 실혐의 결과로 미루어 낮은 용량의 haloperidol을 장기간 투여했을 때 뇌내 DA계에 수용체증식이 나타나며 항정신병 효과의 발현과도 관련성이 시사된다. 이러한 결과는 최근 거론되고 있는 항정신병약물의 저용량투여를 간접적으로 지지하는 것으로 생각되며 DA계의 연동을 알리는 다른 생물학적 지표와의 관련성을 살피면 흥미로운 결과를 얻을 것으로 기대된다.

• 한국의학물리학회지:의학물리
• /
• 제5권2호
• /
• pp.57-68
• /
• 1994

선형가속기에 의한 뇌정위적 방사선수술에 적용되는 원형 소조사변의 선량분포를 측정하기 위해 측정기 선정 이유와 선축 결정, 자체 제작한 소형 물 팬톰에 의한 선량분포 측정시 고려해야 할 점에 대해 논의하고, 치료계획에 필요한 자료인 Clinac-18의 10MV X-선의 TMR, OAR, 조사면 계수와 같은 선량분포 측정결과를 보고하고자 한다. 뇌정위적 방사선수술에 권고되고 있는 조사면 크기가 3cm 이하의 작은 조사면에 대한 선량 분포를 측정하기 위해서는 크기나 감도에 있어서 적합한 p-형 실리콘(Si) 검출기가 선량에 대한 선형성과 선량율 독립성이 적합한지 측정에 의해 판단하였다. 크기와 형태가 같은 아크릴 통을 두 개 제작하여 호스로 연결하여 하나는 물 팬톰으로 이용하고 다른 하나는 높이를 조절하여 측정기의 깊이를 조절하였다. 측정할 위치에서 직각 방향의 측방선량분포를 측정하여 선축의 위치를 찾았다. SAD 100cm 위치에서 조사면 크기 10, 20, 30, 40mm 네 개 콘에 대하여 TMR을 측정하였으며, 일정한 선원-측정기간 거리(SCD)에서 최대선량점깊이(d$_{max}$) 및 6, 10, 15cm 깊이에서 OAR을 측정하여 비교하였다. 조사면 계수는 MU당 SAD, d$_{max}$에서 콘에 대한 선량으로 실리콘 검출기로 측정하였다. 실리콘 검출기는 선량에 대한 선형성이 거의 완벽하였으며 감도는 선량율이 증가함에 따라 감소하였다. 낮은 선량율 때문에 조사면 밖의 선량을 약간 과대평가할 수 있을지라도 100MU/min 이상의 선량율에 대해서는 일정하였다. 직각 방향의 측방선량분포 측정에 의하여 선축을 찾는 방식은 간편하였다. 1cm 두께의 아크릴 판을 보조 물통 아래에 삽입ㆍ제거하는 방식으로 측정기의 깊이 조절도 간편하면서 정확하였다. 측정에 의한 TMR, OAR, 조사면 계수는 충분히 정확하여 뇌정위적 방사선수술의 치료계획에 이용할 수 있었으며, OAR은 조사면 범위 내에서는 깊이에 거의 무관하였다. 실리콘 검출기는 소조사면 선량분포 측정에 적합하였으며 직각 방향의 측방선량분포의 측정으로 0.05mm까지 정확히 선축을 찾을 수 있었고, 보조 물통과 아크릴 판을 이용하여 측정기의 깊이를 조절하는 것이 용이하였다. TMR, OAR, 조사면계수의 측정치는 뇌정위적 방사선수술의 치료 계획에 이용할 수 있을 정도로 정확하였으며, OAR은 하나의 깊이에서 측정해도 충분할 것이라고 사료된다.

• 한국방사선학회논문지
• /
• 제5권5호
• /
• pp.261-265
• /
• 2011

이 연구의 목적은 진단방사선촬영에서 환자의 피부선량을 측정하는 나노도트선량계의 에너지의존성에 대한 보정인자들을 구하는 것이다. 보정인자들은 랜다우어사에서 제공한 팬텀 정에 관한 X-선에 상대적인 선량계의 에너지반응그래프와 로사도 등이 발표한 IEC의 RQR 표준방사선 품질들에 대한 평균에너지 값들을 사용하여 구하였다. 결과들은 관전압 40-150 kVp에서 1-1.33의 보정인자들을 나타냈다. 얻어진 보정인자들은 각 관전압에서 정확한 피부선량 측정을 위하여 임상에 사용하는데 유용할 것으로 생각된다.

• 제어로봇시스템학회논문지
• /
• 제10권12호
• /
• pp.1148-1154
• /
• 2004

The goal of this paper is to verity that the gradual reduction of drug dose (GRDD), which has already been shown by authors to be effective for a simplified HIV infection model, still works for a more realistic model. While the simplified HIV infection model does not take into account an helper-independent CTL, the five state nonlinear model proposed by Wodarz describes the dynamics of both helper-dependent and helper-independent CTL in HIV infection. In this paper, it is shown that, by applying GRDD to Wodarz's five state HIV infection model, the state of HIV infected patient converges to that of non-progressor whose immune response is excited so that his symptom would not be developed into AIDS. Roughly speaking, GRDD is 'slow reduction of dose after the maximum dose for a certain period.' It turns out that an equilibrium representing non-progressor is locally asymptotically stable for the most values of drug dosage, which is required to hold in order to apply GRDD. Simulation results establish that GRDD is still considerably effective both for an AIDS patient and a patient who has been on HAART for a long time.